What is 10-OXO-DELTA-6A-TETRAHYDROCANNABINOL (OTHC)?

Cannabis contains over 100 identified cannabinoids. Most will never receive dedicated pharmacological research. OTHC — 10-oxo-delta-6a-tetrahydrocannabinol — sits at the very edge of that group: a compound confirmed to exist in the cannabis plant, structurally characterized, but with virtually no biological or clinical research to date.

This post takes an honest approach. Where data exists, we present it. Where it doesn’t, we say so clearly and explain what structural chemistry can and cannot tell us about a compound’s likely effects.

What Is OTHC?

OTHC is the abbreviated name for 10-oxo-delta-6a(10a)-tetrahydrocannabinol — a naturally occurring minor cannabinoid in Cannabis sativa L. Its IUPAC name describes a THC-type terpenophenolic structure in which a ketone (oxo) group has been added at carbon position 10, and the double bond is positioned at the delta-6a location rather than delta-9 as in Δ9-THC. The molar mass is 328.4 g/mol, slightly heavier than THC’s 314.46 g/mol, reflecting the addition of an oxygen-containing functional group (New Phase Blends, 2023).

OTHC appears in cannabis as a trace constituent and has been catalogued in cannabinoid identification studies. Its structural relationship to THC classifies it within the THC family of cannabinoids, but the structural differences from Δ9-THC are significant enough to potentially produce meaningfully different pharmacological behavior.

Structure and Chemistry

The defining structural feature of OTHC is the ketone (carbonyl) group at position 10 of the cyclohexene ring, combined with a double bond at the delta-6a position rather than delta-9. This distinguishes it from standard Δ9-THC, Δ8-THC, and other THC isomers.

A computational chemistry analysis published in ACS Omega (Ramírez et al., 2019) examined 468 Cannabis sativa metabolites and their physicochemical properties. The analysis noted that the additional oxo (carbonyl) group at position 10 in OTHC makes the molecule more polar than Δ9-THC, with one more hydrogen-bond donor and one more hydrogen-bond acceptor. This increased polarity has a specific pharmacological implication: more polar cannabinoids have reduced ability to partition into cell membranes, which is required for interaction with G-protein-coupled receptors (GPCRs) like CB1 and CB2 (Ramírez et al., 2019). This suggests OTHC may have lower membrane penetration and potentially weaker or different receptor activity compared to Δ9-THC — though this is computational inference, not experimental confirmation.

What We Know — And What We Don’t

Being transparent about the state of knowledge here is essential. The following is an accurate summary:

What is confirmed: OTHC exists as a naturally occurring trace compound in cannabis. Its molecular structure is characterized. It belongs to the THC family of terpenophenolic cannabinoids. Its molecular formula and molar mass are established. Computational analysis suggests increased polarity compared to Δ9-THC (Ramírez et al., 2019; New Phase Blends, 2023).

What is unknown: Whether OTHC is psychoactive. Whether it binds to CB1, CB2, or other receptors. Whether it has any therapeutic properties. What its bioavailability, metabolism, or pharmacokinetics are in humans or animals. Whether it occurs in concentrations sufficient to have any biological effect in cannabis consumers (New Phase Blends, 2023; Wellspring CBD, 2022).

Why Is Research So Limited?

OTHC’s research vacuum reflects several compounding factors that affect most minor cannabinoids but hit the most obscure ones especially hard. Federal Schedule I classification of cannabis in the United States has historically made cannabinoid research difficult, expensive, and slow. Pharmaceutical companies have little commercial incentive to investigate trace-level compounds with no established activity. And with so many cannabinoids competing for limited research resources, the ones with the clearest activity signals — THC, CBD, CBDV, CBDA — naturally attract the most attention (New Phase Blends, 2023).

The result is a compound that has existed in the scientific literature primarily as a name in cannabinoid catalogues rather than as a subject of active investigation. As analytical chemistry improves and regulatory barriers ease, this may change — but the timeline is uncertain.

OTHC, CBT, and the Oxidized Cannabinoid Family

OTHC’s structural features link it to the cannabitriol (CBT) family of oxidized cannabinoids, which includes compounds formed through the oxidative transformation of THC. Chan et al. (1976) described the structure of cannabitriol, noting its relationship to oxidized THC metabolites — a group that includes compounds bearing additional hydroxyl or ketone groups at various positions. OTHC’s oxo group at C-10 positions it in this broader class of oxidized THC-type compounds, some of which are formed naturally in aged or heat-exposed cannabis and others that may result from metabolic oxidation in the body (New Phase Blends, 2023; Chan et al., 1976).

Frequently Asked Questions

The Bottom Line

OTHC is a genuine entry on the cannabis cannabinoid roster, but it is also one of the most honest examples of how large the gap between “identified” and “understood” can be in cannabinoid science. The compound exists. Its structure is known. And beyond that, we’re operating largely in the dark.

Computational chemistry gives us a reasonable hypothesis — increased polarity likely reduces its membrane interaction and may limit its receptor activity compared to Δ9-THC — but hypotheses are not pharmacology. Until dedicated in vitro, in vivo, or clinical studies are conducted, OTHC remains a cannabinoid in name but a mystery in function.

For anyone building a complete picture of the cannabis cannabinoid family, OTHC deserves a place on the map — but with a clear marker indicating how little of that territory has actually been explored.

Nothing in this article constitutes medical advice. Always consult a qualified healthcare provider before making any decisions about supplementation or treatment.